322 related articles for article (PubMed ID: 9715299)
1. In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh immunoglobulins.
Mehta YS; Badakere SS
J Postgrad Med; 1996; 42(2):46-9. PubMed ID: 9715299
[TBL] [Abstract][Full Text] [Related]
2. Recombinant anti-idiotypic antibodies inhibit human natural anti-glycoprotein (GP)IIb/IIIa autoantibodies.
Escher R; Vogel M; Escher G; Miescher S; Stadler BM; Berchtold P
J Autoimmun; 2002 Feb; 18(1):71-81. PubMed ID: 11869049
[TBL] [Abstract][Full Text] [Related]
3. Idiopathic autoimmune thrombocytopenia: evidence for redistribution of platelet antibodies into the circulation after immunoadsorption treatment.
Leitner GC; Stiegler G; Horvath M; Hoecker P; Sagaster P; Panzer S
Am J Hematol; 2003 May; 73(1):44-7. PubMed ID: 12701120
[TBL] [Abstract][Full Text] [Related]
4. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study.
Peng J; Ma SH; Liu J; Hou Y; Liu XM; Niu T; Xu RR; Guo CS; Wang XM; Cheng YF; Ni H; Hou M
J Thromb Haemost; 2014 Apr; 12(4):497-504. PubMed ID: 24517219
[TBL] [Abstract][Full Text] [Related]
5. Platelet-associated anti-glycoprotein (GP) IIb-IIIa autoantibodies in chronic immune thrombocytopenic purpura mainly recognize cation-dependent conformations: comparison with the epitopes of serum autoantibodies.
Kosugi S; Tomiyama Y; Shiraga M; Kashiwagi H; Mizutani H; Kanakura Y; Kurata Y; Matsuzawa Y
Thromb Haemost; 1996 Feb; 75(2):339-45. PubMed ID: 8815587
[TBL] [Abstract][Full Text] [Related]
6. Circulating antiplatelet antibody specificity in children with immune thrombocytopenic purpura at onset.
Biglino P; Perutelli P; Mori PG
Haematologica; 1997; 82(1):127. PubMed ID: 9107104
[No Abstract] [Full Text] [Related]
7. [Study on autoimmune thrombocytopenic purpura related antibody].
Lu L; Hou M; Shi Y; Qin P; Peng J; Zhu YY; Zhang MH
Zhonghua Xue Ye Xue Za Zhi; 2003 Sep; 24(9):477-9. PubMed ID: 14575592
[TBL] [Abstract][Full Text] [Related]
8. [Identification of human platelet specific functional antibody and its fragments].
Chu XX; Hou M; Zhu YY; Peng J; Ji XB; Zhang F; Wang L
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3464-8. PubMed ID: 16686061
[TBL] [Abstract][Full Text] [Related]
9. Fab-mediated binding of glycoprotein Ib/IX and IIb/IIIa specific antibodies in chronic idiopathic thrombocytopenic purpura.
Hou M; Stockelberg D; Kutti J; Wadenvik H
Br J Haematol; 1995 Dec; 91(4):944-50. PubMed ID: 8547147
[TBL] [Abstract][Full Text] [Related]
10. Role of antiidiotypic antibodies on the clinical course of idiopathic thrombocytopenic purpura.
Mehta YS; Ghosh K; Badakere SS; Pathare AV; Mohanty D
J Lab Clin Med; 2003 Aug; 142(2):113-20. PubMed ID: 12960958
[TBL] [Abstract][Full Text] [Related]
11. Target platelet antigens of autoantibodies in patients with primary biliary cirrhosis.
Feistauer SM; Penner E; Mayr WR; Panzer S
Hepatology; 1997 Jun; 25(6):1343-5. PubMed ID: 9185750
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of chronic immune thrombocytopenic purpura.
Cines DB; McMillan R
Curr Opin Hematol; 2007 Sep; 14(5):511-4. PubMed ID: 17934360
[TBL] [Abstract][Full Text] [Related]
13. The isolation and characterisation of antiplatelet antibodies.
Hamidpour M; Behrendt M; Griffiths B; Partridge L; Lindsey N
Eur J Haematol; 2006 Apr; 76(4):331-8. PubMed ID: 16519705
[TBL] [Abstract][Full Text] [Related]
14. Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment.
Levy Y; Sherer Y; Ahmed A; Fabbrizzi F; Terryberry J; Shen GQ; Peter JB; Shoenfeld Y
Nat Immun; 1998; 16(5-6):207-14. PubMed ID: 11061589
[TBL] [Abstract][Full Text] [Related]
15. [Study on the relations between HLA-DRB1 alleles and idiopathic thrombocytopenic purpura in children].
Wang H; Shen B; Yan W; Hou M; Zhu N; Qi H; Hou H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Aug; 19(4):290-4. PubMed ID: 12170464
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet antibodies in childhood idiopathic thrombocytopenic purpura.
Ozsoylu S
Am J Hematol; 1996 Apr; 51(4):328. PubMed ID: 8602636
[No Abstract] [Full Text] [Related]
17. Harmful and beneficial antibodies in immune thrombocytopenic purpura.
Imbach PA
Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):25-30. PubMed ID: 8033430
[TBL] [Abstract][Full Text] [Related]
18. Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia.
Kiefel V; Freitag E; Kroll H; Santoso S; Mueller-Eckhardt C
Ann Hematol; 1996 Apr; 72(4):280-5. PubMed ID: 8624385
[TBL] [Abstract][Full Text] [Related]
19. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.
Rodeghiero F
Eur J Haematol Suppl; 2008 Feb; (69):19-26. PubMed ID: 18211569
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of IVIG action in immune thrombocytopenic purpura.
Hansen RJ; Balthasar JP
Clin Lab; 2004; 50(3-4):133-40. PubMed ID: 15074465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
